Company Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Hangzhou Tigermed Consulting Co., Ltd

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-04-29 EDT			5-day change	1st Jan Change
59.11 ^CNY	-0.94%		+18.86%	+7.53%

04-25	Hangzhou Tigermed Consulting’s Profit Down 59% in Q1	MT
04-25	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024	CI

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows:

- provision of clinical trial services and related technological services (51.8%);

- provision of clinical research consulting services (48.2%).

China accounts for 46% of sales.

CNY in Million	2022	Weight	2023	Weight	Delta
Clinical Trial Technical Services 56.4 %	4,125	58.2 %	4,168	56.4 %	+1.04%
Clinical Trial-related Services and Laboratory Services 42.3 %	2,876	40.6 %	3,121	42.3 %	+8.51%
Other Business 1.3 %	84	1.2 %	95	1.3 %	+13.10%

CNY in Million	2022	Weight	2023	Weight	Delta
China 57.3 %	3,602	50.8 %	4,235	57.3 %	+17.57%
Overseas 42.7 %	3,484	49.2 %	3,150	42.7 %	-9.60%

Managers	Title	Age	Since
Xiao Chun Cao CEO	Chief Executive Officer	55	04-12-31
Hao Wu PSD	President	56	19-12-31
Xiao Ping Ye CHM	Chairman	61	-
Cheng Cheng Yang DFI	Director of Finance/CFO	50	22-08-31
Zeng Yu Wen COO	Chief Operating Officer	43	10-02-28
Xiaori Li SEC	Corporate Secretary	41	21-09-16
Helen Yin PRN	Corporate Officer/Principal	-	-
Abe Li PRN	Corporate Officer/Principal	-	-
Yin Kwan Ho SEC	Corporate Secretary	47	22-06-26
Li Li Meng PRN	Corporate Officer/Principal	49	09-07-31

Members of the board	Title	Age	Since
Xiao Chun Cao CEO	Chief Executive Officer	55	04-12-31
Bing Hui Zhang CHM	Chairman	61	20-04-27
Xiao Ping Ye CHM	Chairman	61	-
Zhi Min Chen BRD	Director/Board Member	64	-
Hua Gang Yuan BRD	Director/Board Member	51	23-04-24
Kai Yu Liu BRD	Director/Board Member	54	20-03-31
Hao Wu PSD	President	56	19-12-31
Zeng Yu Wen COO	Chief Operating Officer	43	10-02-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	123,124,800	123,124,800 ( 100.00 %)	0	69.94 %
Stock B	1	749,293,420	487,069,654 ( 65.00 %)	0

Name	Equities	%	Valuation
Sands Capital Management LLC 11.86 %	14,606,581	11.86 %	55 M ¥
E Fund Management Co., Ltd. 10.38 %	12,777,409	10.38 %	48 M ¥
Baillie Gifford & Co. 8.301 %	10,220,000	8.301 %	39 M ¥
Ninety One UK Ltd. 6.141 %	7,560,500	6.141 %	29 M ¥
Canada Pension Plan Investment Board 6.007 %	7,395,500	6.007 %	28 M ¥
UBS Asset Management Switzerland AG 5.104 %	6,283,832	5.104 %	24 M ¥
Bank of Communications Schroder Fund Management Co., Ltd. 2.362 %	2,907,714	2.362 %	11 M ¥
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 1.971 %	2,426,200	1.971 %	9 M ¥
BlackRock Fund Advisors 1.775 %	2,185,400	1.775 %	8 M ¥
Huatai-PineBridge Fund Management Co., Ltd. 1.520 %	1,871,900	1.520 %	7 M ¥

Name	Equities	%	Valuation
Fiera Capital (UK) Ltd. 0.1081 %	613,400	0.1081 %	2 M ¥

Name	Equities	%	Valuation
Xiao Ping Ye 74.09 %	132,929,656	74.09 %	978 M ¥
Xiao Chun Cao 21.60 %	38,746,330	21.60 %	285 M ¥
Yin Zhuan 5.696 %	10,220,000	5.696 %	75 M ¥
Xiaori Li 0.006164 %	11,058	0.006164 %	81 320 ¥

Name	Equities	%	Valuation
Zhong Ou Asset Management Co., Ltd 8.813 %	50,224,412	8.813 %	369 M ¥
Xiao Ping Ye 7.775 %	44,309,885	7.775 %	326 M ¥
Bank of Communications Schroder Fund Management Co., Ltd. 4.847 %	27,621,094	4.847 %	203 M ¥
Temasek Holdings Pte Ltd. (Investment Management) 3.419 %	19,483,875	3.419 %	143 M ¥
Hwabao WP Fund Management Co., Ltd. 2.491 %	14,194,306	2.491 %	104 M ¥
Xiao Chun Cao 2.266 %	12,915,444	2.266 %	95 M ¥
China Merchants Fund Management Co., Ltd. 2.042 %	11,636,241	2.042 %	86 M ¥
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 1.892 %	10,779,694	1.892 %	79 M ¥
Xiao Li Shi 1.881 %	10,721,575	1.881 %	79 M ¥
HuaAn Fund Management Co., Ltd. 1.344 %	7,657,157	1.344 %	56 M ¥

Name	Equities	%	Valuation
FRONTAGE HOLDINGS CORPORATION 59.99%	1,258,984,090	59.99%	231,640,483 $
DREAMCIS, INC. 59.57%	14,123,680	59.57%	31,316,012 $
HANGZHOU TIGERMED CONSULTING CO., LTD 0.69%	3,909,800	0.69%	28,752,317 $
ANHUI WANBANG PHARMACEUTICAL TECHNOLOGY CO., LTD. 1.53%	776,850	1.53%	5,373,231 $

Hangzhou Tigermed Consulting Co., Ltd.

20/F Block 8, Room 2001-2010 No.19 Jugong Road, Xixiang Street

310051, Hangzhou

+86 571 2888 7227

http://www.tigermed.net

address Hangzhou Tigermed Consulting Co., Ltd(300347)

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

59.11 CNY

Average target price

73.04 CNY

Spread / Average Target

+23.56%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANGZHOU TIGERMED CONSULTING CO., LTD	+7.53%	6.6B
IQVIA HOLDINGS INC.	+0.17%	42.19B
MODERNA, INC.	+10.92%	42.24B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+5.23%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.2B
MEDPACE HOLDINGS, INC.	+26.69%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.57%	10.4B

Other Biotechnology & Medical Research